Asterion Therapeutics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Asterion Therapeutics
Largest movements
- Intangible fixed assets -€3,781
down €3,781 (-21.6%), from €17,537 to €13,756
- Receivables within one year +€3,032
up €3,032 (+16.1%), from €18,850 to €21,882
of which Other amounts receivable: +€3,032
- Profit (loss) carried forward -€95,406
down €95,406 (-58.3%), from -€163,619 to -€259,025
- Provisions +€75,000
new in 2025: €75,000
- Debts after one year +€23,035
up €23,035 (+16.6%), from €138,496 to €161,531
- Trade debts -€4,649
down €4,649 (-13.2%), from €35,213 to €30,564
- Other debts +€1,350
up €1,350 (+33.9%), from €3,977 to €5,327
- Provisions +€75,000
new in 2025: €75,000
- Purchases and services -€12,786
no longer reported in 2025 (was €12,786)
- Write-downs -€9,655
down €9,655, from €4,828 to -€4,827
- Gross operating margin -€2,662
down €2,662 (-20.8%), from -€12,786 to -€15,448
- Financial income -€2,600
down €2,600 (-100%), from €2,600 to €0
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €59,067 | €58,464 | -€603 | -1.0% |
| Fixed assets | 21/28 | €17,537 | €13,756 | -€3,781 | -21.6% |
| Intangible fixed assets | 21 | €17,537 | €13,756 | -€3,781 | -21.6% |
| Current assets | 29/58 | €41,530 | €44,708 | +€3,178 | +7.7% |
| Amounts receivable after more than one year | 29 | €22,675 | €22,675 | +€0 | 0.0% |
| Trade receivables | 290 | €22,675 | €0 | -€22,675 | -100% |
| Other amounts receivable | 291 | - | €22,675 | +€22,675 | |
| Amounts receivable within one year | 40/41 | €18,850 | €21,882 | +€3,032 | +16.1% |
| Trade receivables | 40 | €6,306 | €6,306 | +€0 | 0.0% |
| Other amounts receivable | 41 | €12,544 | €15,576 | +€3,032 | +24.2% |
| Cash at bank and in hand | 54/58 | €5 | €151 | +€146 | +2,926% |
| Total equity and liabilities | 10/49 | €59,067 | €58,464 | -€603 | -1.0% |
| Equity | 10/15 | -€118,619 | -€214,025 | -€95,406 | -80.4% |
| Contributions | 10/11 | €45,000 | €45,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€163,619 | -€259,025 | -€95,406 | -58.3% |
| Provisions and deferred taxes | 16 | - | €75,000 | +€75,000 | |
| Provisions for liabilities and charges | 160/5 | - | €75,000 | +€75,000 | |
| Other liabilities and charges | 164/5 | - | €75,000 | +€75,000 | |
| Amounts payable | 17/49 | €177,686 | €197,489 | +€19,803 | +11.1% |
| Amounts payable after more than one year | 17 | €138,496 | €161,531 | +€23,035 | +16.6% |
| Financial debts | 170/4 | €138,496 | €161,531 | +€23,035 | +16.6% |
| Amounts payable within one year | 42/48 | €39,190 | €35,890 | -€3,300 | -8.4% |
| Trade debts | 44 | €35,213 | €30,564 | -€4,649 | -13.2% |
| Suppliers | 440/4 | €35,213 | €30,564 | -€4,649 | -13.2% |
| Other amounts payable | 47/48 | €3,977 | €5,327 | +€1,350 | +33.9% |
| Accrued charges and deferred income | 492/3 | - | €67 | +€67 | |
| Goods, raw materials, services and sundry goods | 60/61 | €12,786 | - | -€12,786 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €4,480 | €5,872 | +€1,392 | +31.1% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €4,828 | -€4,827 | -€9,655 | |
| Provisions for liabilities and charges: additions (uses and reversals) | 635/8 | - | €75,000 | +€75,000 | |
| Other operating charges | 640/8 | €168 | €520 | +€352 | +209% |
| Gross operating margin | 9900 | -€12,786 | -€15,448 | -€2,662 | -20.8% |
| Operating profit (loss) | 9901 | -€22,262 | -€92,012 | -€69,750 | -313% |
| Financial income | 75/76B | €2,600 | €0 | -€2,600 | -100% |
| Recurring financial income | 75 | €2,600 | €0 | -€2,600 | -100% |
| Financial charges | 65/66B | €3,603 | €3,393 | -€210 | -5.8% |
| Recurring financial charges | 65 | €3,603 | €3,393 | -€210 | -5.8% |
| Profit (loss) for the period before taxes | 9903 | -€23,265 | -€95,406 | -€72,141 | -310% |
| Profit (loss) for the period | 9904 | -€23,265 | -€95,406 | -€72,141 | -310% |
| Profit (loss) for the period to be appropriated | 9905 | -€23,265 | -€95,406 | -€72,141 | -310% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.